Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/24/2025

Pediatric Rhinosinusitis Management

Introduction to Pediatric Rhinosinusitis

  • Rhinosinusitis in children is a common condition that can be classified as viral, post-viral, or bacterial 1
  • Acute post-viral rhinosinusitis is a self-limiting disease in most children 2

Evidence-Based Treatment Recommendations

  • Herbal medicines, such as BNO1016 tablets, Pelargonium sidoides drops, and Myrtol capsules, have shown significant impact on symptoms of acute post-viral rhinosinusitis without significant adverse events, making them a first-line treatment option 1, 3
  • Bacterial lysates, specifically OM-85-BV, have shown benefit in shortening the duration of illness in children with post-viral rhinosinusitis 2, 3
  • Nasal saline irrigation may be beneficial, with high-volume saline rinsing having larger effects on purulent rhinorrhea and post-nasal drip compared to low-volume rinsing 1, 3
  • Antibiotics are not recommended for children with acute post-viral rhinosinusitis as they are not associated with greater cure or significant improvement, according to the American Academy of Pediatrics 2, 4
  • Nasal corticosteroids are not recommended due to very low quality evidence, despite showing some effectiveness in reducing total symptom score 2
  • Antihistamines show no additive effect over standard treatment and are not recommended 2
  • Over-the-counter cough and cold medications should not be used in children under 2 years due to lack of proven efficacy and potential for serious toxicity 5
  • Decongestants (oral/nasal) have no studies evaluating their effect on resolution or reduction of symptoms of post-viral rhinosinusitis in children, and the American Academy of Pediatrics advises against using topical decongestants in children under 1 year 1, 5

Special Considerations

  • The American Academy of Pediatrics recommends amoxicillin as the first-line therapy for uncomplicated acute bacterial rhinosinusitis in children, but this information is not directly cited 4

When to Seek Medical Attention

  • Immediate referral is required if alarm symptoms such as displaced globe are present 4
  • Parents should seek medical attention if the child exhibits respiratory rate >70 breaths/min (infants) or >50 breaths/min (older children), difficulty breathing, or persistent high fever, as recommended by the American Academy of Pediatrics 5

Follow-up Recommendations

  • Reassess management if there is either worsening of symptoms or failure to improve within 72 hours of initial management, as recommended by the American Academy of Pediatrics 4
  • Children being cared for at home should be reviewed if symptoms are deteriorating or not improving after 48 hours 5

Important Caveats

  • Chest physiotherapy is not beneficial and should not be performed in children with respiratory infections, as stated by the American Academy of Pediatrics 5
  • Environmental factors like tobacco smoke exposure should be addressed as they can exacerbate respiratory symptoms, according to the American Academy of Pediatrics 5
  • For persistent cough beyond 4 weeks, further evaluation may be needed to identify underlying causes, as recommended by the American Academy of Pediatrics 5

First-Line Treatment for Pediatric Rhinosinusitis

Diagnosis and Treatment

  • For children with acute bacterial rhinosinusitis, the American Academy of Pediatrics recommends amoxicillin at 45 mg/kg/day (or 80-90 mg/kg/day in high-risk situations) as the first-line antibiotic treatment, with a maximum dose of 2 grams per dose 6
  • The American Academy of Pediatrics suggests that ABRS should be suspected when symptoms persist beyond 10 days without improvement, when symptoms worsen after initial improvement, or when severe symptoms are present for at least 3-4 consecutive days 6
  • For children who cannot tolerate oral medication or when adherence is uncertain, a single-dose ceftriaxone 50 mg/kg IV or IM can be used, effective against 95-100% of the three major pathogens (6]
  • The recommended duration of treatment for most cases of ABRS is 5-10 days, balancing efficacy with minimizing resistance 6

Medication Usage

  • The American Academy of Pediatrics recommends against using OTC cough and cold medications in children under 2 years due to lack of efficacy and potential toxicity, and to avoid them in children under 6 years 7
  • Topical decongestants are not recommended under age 1 year due to narrow therapeutic window and cardiovascular/CNS risks, with a risk of rhinitis medicamentosa after 3-4 days of use 7

Patient Assessment

  • Reevaluation within 72 hours is necessary if no improvement occurs or symptoms worsen at any time, with immediate referral required for alarm symptoms such as displaced globe, respiratory distress, or persistent high fever despite treatment 8
  • The American Academy of Otolaryngology-Head and Neck Surgery suggests that watchful waiting for up to 7 days with symptomatic relief is appropriate for ABRS when follow-up is ensured 8

Microbiology Considerations

  • The three major pathogens in pediatric ABRS are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, with approximately 10-15% of S. pneumoniae being penicillin-nonsusceptible nationally 6
  • Between 10-42% of H. influenzae and nearly 100% of M. catarrhalis produce β-lactamase, justifying the use of high-dose amoxicillin or amoxicillin-clavulanate in high-risk populations 6